PE20230461A1 - Compuestos para tratar o inhibir la recidiva de la leucemia mieloide aguda - Google Patents
Compuestos para tratar o inhibir la recidiva de la leucemia mieloide agudaInfo
- Publication number
- PE20230461A1 PE20230461A1 PE2022001990A PE2022001990A PE20230461A1 PE 20230461 A1 PE20230461 A1 PE 20230461A1 PE 2022001990 A PE2022001990 A PE 2022001990A PE 2022001990 A PE2022001990 A PE 2022001990A PE 20230461 A1 PE20230461 A1 PE 20230461A1
- Authority
- PE
- Peru
- Prior art keywords
- myeloid leukemia
- acute myeloid
- alkyl
- recurrence
- compounds
- Prior art date
Links
- 208000031261 Acute myeloid leukaemia Diseases 0.000 title abstract 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 125000004423 acyloxy group Chemical group 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto de formula (I), donde cada Q, Y y Z son N o C; X es N o C-Ra; cada enlace discontinuo es independientemente un enlace simple o doble; R1 es alquilo, alquenilo, alquinilo, amino, acilamino, cicloalquilo, cicloalquilalquilo, entre otros; W es N, R2 esta ausente, y A1 y A2 son cada uno CH2; Ra se selecciona entre H, halo, CN y alquilo; R9 se selecciona entre H, halo, alquilo, alcoxi, hidroxi, aciloxi y amino; R10 es H o alcoxi; R11 es ariloxi, heteroariloxi, arilalquilo, alcoxicarbonilo, ureido o -C(O)-arilo; y R12 se selecciona entre H, halo, CN, alquilo, alcoxi, hidroxi y aciloxi. Dichos compuestos son utiles para tratar la leucemia mieloide aguda o inhibir la recidiva de la leucemia mieloide aguda y para inhibir el crecimiento y/o destruir celulas madre leucemicas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2020/079464 WO2021184154A1 (en) | 2020-03-16 | 2020-03-16 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
| PCT/US2021/022322 WO2021188417A1 (en) | 2020-03-16 | 2021-03-15 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230461A1 true PE20230461A1 (es) | 2023-03-14 |
Family
ID=77767943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001990A PE20230461A1 (es) | 2020-03-16 | 2021-03-15 | Compuestos para tratar o inhibir la recidiva de la leucemia mieloide aguda |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11963960B2 (es) |
| EP (1) | EP4121430A4 (es) |
| JP (1) | JP2023518035A (es) |
| KR (1) | KR20220154164A (es) |
| CN (1) | CN115298180A (es) |
| AR (1) | AR121570A1 (es) |
| AU (1) | AU2020436612A1 (es) |
| BR (1) | BR112022018345A2 (es) |
| CA (1) | CA3168988A1 (es) |
| IL (1) | IL296296A (es) |
| MX (1) | MX2022011407A (es) |
| PE (1) | PE20230461A1 (es) |
| TW (1) | TW202200583A (es) |
| WO (2) | WO2021184154A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020436612A1 (en) | 2020-03-16 | 2022-09-01 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
| JP2023524597A (ja) | 2020-05-08 | 2023-06-12 | ハリア・セラピューティクス・インコーポレイテッド | Ｎｅｋ７キナーゼの阻害剤 |
| CN113861179A (zh) * | 2021-10-22 | 2021-12-31 | 上海应用技术大学 | 一种新型flt3激酶抑制剂及其合成与应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1134439C (zh) | 1997-03-19 | 2004-01-14 | 艾博特股份有限两合公司 | 吡咯并[2,3d]嘧啶类化合物及它们作为酪氨酸激酶抑制剂的用途 |
| US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| DK1212327T3 (da) * | 1999-09-17 | 2003-12-15 | Abbott Gmbh & Co Kg | Pyrazolopyrimidiner som terapeutiske midler |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| MXPA03008560A (es) * | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| EP1730148A4 (en) * | 2004-02-03 | 2009-08-19 | Abbott Lab | USE OF AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS |
| CA2681756C (en) | 2007-03-28 | 2015-02-24 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| EP2878601B1 (en) * | 2012-07-27 | 2018-03-28 | Riken | Agent for treating or controlling recurrence of acute myelogenous leukemia |
| WO2014063061A1 (en) * | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| CN105017256A (zh) * | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| CN105481862B (zh) | 2015-01-21 | 2018-08-21 | 中国科学院合肥物质科学研究院 | Flt3激酶的新型抑制剂及其用途 |
| GB201508747D0 (en) | 2015-05-21 | 2015-07-01 | Univ Edinburgh | Compounds |
| US20190255056A1 (en) * | 2016-09-15 | 2019-08-22 | Riken | A hck inhibitor and a bcl-2 inhibitor for treating acute myeloid leukemia |
| TWI762939B (zh) | 2019-05-31 | 2022-05-01 | 大陸商海思科醫藥集團股份有限公司 | Btk抑制劑環衍生物及其製備方法和藥學上的應用 |
| WO2020263935A1 (en) | 2019-06-24 | 2020-12-30 | Dana-Farber Cancer Institute, Inc. | Hck degraders and uses thereof |
| AU2020362194A1 (en) | 2019-10-08 | 2022-05-19 | Dana-Farber Cancer Institute, Inc. | A pyrazolopyrimidine derivative as a HCK inhibitor for use in therapy, in particular MYD88 mutated diseases |
| AU2020436612A1 (en) | 2020-03-16 | 2022-09-01 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
-
2020
- 2020-03-16 AU AU2020436612A patent/AU2020436612A1/en active Pending
- 2020-03-16 WO PCT/CN2020/079464 patent/WO2021184154A1/en active Application Filing
-
2021
- 2021-03-12 AR ARP210100645A patent/AR121570A1/es unknown
- 2021-03-15 JP JP2022555625A patent/JP2023518035A/ja active Pending
- 2021-03-15 WO PCT/US2021/022322 patent/WO2021188417A1/en unknown
- 2021-03-15 MX MX2022011407A patent/MX2022011407A/es unknown
- 2021-03-15 KR KR1020227035324A patent/KR20220154164A/ko unknown
- 2021-03-15 CN CN202180016180.0A patent/CN115298180A/zh active Pending
- 2021-03-15 PE PE2022001990A patent/PE20230461A1/es unknown
- 2021-03-15 US US17/201,827 patent/US11963960B2/en active Active
- 2021-03-15 BR BR112022018345A patent/BR112022018345A2/pt not_active Application Discontinuation
- 2021-03-15 IL IL296296A patent/IL296296A/en unknown
- 2021-03-15 EP EP21772015.0A patent/EP4121430A4/en active Pending
- 2021-03-15 CA CA3168988A patent/CA3168988A1/en active Pending
- 2021-03-16 TW TW110109254A patent/TW202200583A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4121430A4 (en) | 2024-04-17 |
| BR112022018345A2 (pt) | 2022-11-08 |
| EP4121430A1 (en) | 2023-01-25 |
| TW202200583A (zh) | 2022-01-01 |
| CN115298180A (zh) | 2022-11-04 |
| IL296296A (en) | 2022-11-01 |
| JP2023518035A (ja) | 2023-04-27 |
| MX2022011407A (es) | 2022-10-13 |
| AU2020436612A1 (en) | 2022-09-01 |
| AR121570A1 (es) | 2022-06-15 |
| US20210299128A1 (en) | 2021-09-30 |
| US11963960B2 (en) | 2024-04-23 |
| WO2021188417A1 (en) | 2021-09-23 |
| KR20220154164A (ko) | 2022-11-21 |
| CA3168988A1 (en) | 2021-09-23 |
| WO2021184154A1 (en) | 2021-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230461A1 (es) | Compuestos para tratar o inhibir la recidiva de la leucemia mieloide aguda | |
| PE20211784A1 (es) | Tolillo sustituido como fungicidas | |
| DE602005025332D1 (de) | 4-ä2-(cycloalkylamino)pyrimidin-4-ylü-(phenyl)imidazolin-2-onderivate als inhibitoren der p38-map-kinase zur behandlung von entzündlichen krankheiten | |
| PE20230737A1 (es) | Inhibidores de sarm1 | |
| PE20021005A1 (es) | Quinazolinas como inhibidores de mmp-13 | |
| AR042042A1 (es) | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular | |
| TNSN07281A1 (en) | Pyrazole derivatives for the inhibition of cdk's and gsk's | |
| PE20070808A1 (es) | COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA | |
| AR092490A2 (es) | Indolil alquil amino derivados sustituidos como inhibidores de la histona desacetilasa | |
| ECSP045317A (es) | Piridinoilpiperidinas como agonistas de 5-ht1f | |
| PE20071322A1 (es) | Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa | |
| PE20060525A1 (es) | Compuestos heterociclicos como inhibidores de cetp | |
| PE20141827A1 (es) | Inhibidores de proteinas quinasas | |
| PE20060363A1 (es) | DERIVADOS DE TETRAAZABENZO[e]AZULENO Y SUS ANALOGOS | |
| PE20140858A1 (es) | Derivados de piperidina como inhibidores de renina | |
| TW200602319A (en) | Indole derivative and use thereof | |
| SV2006002069A (es) | Procedimiento para la obtención de un compuesto aplicado en el tratamiento de esquizofrenia y/o anomalías de glucorregulación | |
| EA200100600A3 (ru) | Новые соединения дифенилмочевины, способ их получения и содержащие их фармацевтические композиции | |
| AR104596A1 (es) | Compuestos de tioéter como inhibidores de la nitrificación | |
| ECSP055693A (es) | Proceso para la síntesis de intermediarios útiles para la síntesis de inhibidores de la tubulina | |
| MX335989B (es) | Compuesto adecuado para el tratamiento de sinucleopatias. | |
| AR127583A1 (es) | Lactamas como inhibidores de cbl-b selectivos sobre c-cbl | |
| AR064331A1 (es) | Combinacion para tratar una infestacion parasitaria | |
| DOP2010000022A (es) | Derivados de pirimidina 934 | |
| PE20231986A1 (es) | Compuesto de heteroarilcarboxamida |